ZVRA NASDAQ
Zevra Therapeutics, Inc.
1W: -3.9%
1M: -11.0%
3M: +2.9%
YTD: +20.6%
1Y: -5.2%
3Y: +138.9%
5Y: +3.8%
$10.05
+0.53 (+5.51%)
Weekly Expected Move ±8.3%
$8
$9
$10
$11
$11
Credit Risk of going bust: lower than 84% of companies Debt: 0.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Zevra Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.5M against a stock market value of $597.1M.
Distance to default 10.75 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $748K (short-term plus half of long-term), stock volatility 60.9%; Altman Z'' 4.62. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Zevra Therapeutics, Inc. would be worth roughly what it owes.
Total debt $1.5M against a stock market value of $597.1M.
Distance to default 10.75 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $748K (short-term plus half of long-term), stock volatility 60.9%; Altman Z'' 4.62. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
10 relationships10
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-07-02
Earliest Filing
2026-03-16
Latest Filing
partner: 4
target: 3
acquirer: 2
investor: 1
Counterparties (Filed by ZVRA)
10 relationshipsCompanies named in ZVRA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Commave Therapeutics SA | — | acquirer | Acquired Zevra's SDX assets and terminated the AZSTARYS License Agreement in exchange for $50 million. | 2026-03-16 | View |
| Computershare, Inc. | — | partner | Rights agent for the Contingent Value Rights Agreement | 2023-11-20 | View |
| Computershare Trust Company, N.A. | — | partner | Affiliate of Computershare, Inc. acting as rights agent | 2023-11-20 | View |
| Acer Therapeutics Inc. | — | target | Target company acquired in the Merger | 2023-11-20 | View |
| Aspen Z Merger Sub, Inc. | ASPU | acquirer | Wholly-owned subsidiary of Zevra used to acquire Acer Therapeutics Inc. | 2023-11-20 | View |
| Latham & Watkins LLP | SWIM | partner | Counsel to the Company for the Registered Direct Offering | 2023-11-20 | View |
| the Investor | — | investor | Healthcare focused investment fund purchasing shares and warrants in the Registered Direct Offering | 2023-11-20 | View |
| Orphazyme A/S | — | target | Sold all assets and operations related to arimoclomol to KemPharm Denmark A/S for $12.8 million. | 2022-06-01 | View |
| Orphazyme A/S in restructuring | — | target | Target of asset purchase agreement for arimoclomol operations. | 2022-05-16 | View |
| RBC Capital Markets, LLC | — | partner | Sales agent for equity distribution agreement | 2021-07-02 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-06-05 | Shareholder Vote; Exhibits | View | |
| 2026-05-06 | Earnings Release; Exhibits | View | |
| 2026-03-16 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Regulation F | Agreement | View |
| 2026-03-09 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-12-17 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-12-02 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-11-20 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-29 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-07 | Completion of Acquisition or Disposition of Assets; Results of Operations and Financial Condition; O | Acquisition | View |
| 2025-03-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-27 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2024-12-06 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2024-11-22 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2024-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-09-20 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2024-08-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR